In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MADIT-CRT: Good News for Devices in Heart Failure, But Will Referring Physicians Care?

Executive Summary

Proponents of cardiac resynchronization devices with a defibrillation function expect the recently released results of the MADIT-CRT trial to give a long-awaited boost to the overall implantable cardioverter defibrillator market. Boston Scientific Corp., the sponsor of the study, expects the FDA to soon expand the indication for its CRT devices to the roughly 70% of heart failure patients worldwide in New York Heart Association heart failure Class I or Class II, reflecting the improvements in hospitalization and ventricular output linked to CRT in the trial.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts